Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13228621 | 0.81 | NPC1 (0.31) | — | |
| SCHEMBL31051598 | 0.79 | — | — | |
| SCHEMBL22425345 | 0.71 | HTT (0.31) | — | |
| Ammonia Solution, Strong SCHEMBL29243645 | 0.70 | HTT (0.30) | — | |
| SCHEMBL2095447 | 0.69 | — | — | |
| SCHEMBL2095444 | 0.67 | — | — | |
| SCHEMBL16065691 | 0.67 | — | — | |
| SCHEMBL22332006 | 0.67 | — | — | |
| SCHEMBL2090860 | 0.67 | NPC1 (0.30) | — | |
| SCHEMBL21188143 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023225664-A1 | LACTAM SUBSTITUTED IMIDAZOPYRIDAZINE IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-11-23 | — | — | WO | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230242537-A1 | IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA N.V. (BE) | 2023-08-03 | — | — | US | disclosed |
| US-20220000890-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | MEDIC LIFE SCIENCES, INC. | 2022-01-06 | — | — | US | disclosed |
| WO-2021220183-A1 | IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | KDM5B 1252/4885HCAR2 703/4885 |
| US-20220000890-A1 | INHIBITORS OF CYCLIN DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CCNK | KDM5B 1162/4885HCAR2 4302/4885 |
| US-20230242537-A1 | IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL2 | KDM5B 1186/4885HCAR2 1356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.